anti-IL-20 + placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Psoriasis
Trial Timeline
Apr 1, 2008 → Jan 1, 2011
NCT ID
NCT01261767About anti-IL-20 + placebo
anti-IL-20 + placebo is a phase 1 stage product being developed by Novo Nordisk for Inflammation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01261767. Target conditions include Inflammation, Psoriasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01038674 | Phase 1 | Completed |
| NCT00818064 | Phase 1 | Completed |
| NCT01261767 | Phase 1 | Terminated |
Competing Products
20 competing products in Inflammation